MSD India appoints Rehan A Khan as Managing Director
Rehan A Khan was also a board member and advisor to several impacts led Private Equity funds and to healthcare companies in Africa, India, and South-East Asia., MSD stated in its recent release.
Mumbai: Biopharmaceutical company, MSD in India recently announced that Rehan A Khan has been appointed as Managing Director, India Region and will be assuming responsibility from January 13, 2020.
Announcing the leadership appointment, DortheMikkelsen, President Asia Pacific Region, MSD said, "I am thrilled to announce the appointment of Rehan A. Khan as Managing Director for MSD in India. Rehan is an accomplished international leader who has led large and complex multinational businesses, covering India, Greater China, Southeast Asia, and across the Asia Pacific with leading multinational companies. His expertise, experience and industry know-how will be invaluable in driving MSD's business in India and helping achieve our vision for patient access to critical therapies".
Rehan has over 20 years of in-depth industry experience, including as President of Asia Pacific with an NYSE-listed dialysis services provider with a presence across 50 cities in Asia and prior to that as Managing Director of a leading pharmaceutical multinational company in India.
More recently, Rehan was an entrepreneur and Founder of First Penguin Capital, an early-stage fund focused on investing in health and consumer tech startups. He was also a board member and advisor to several impacts led Private Equity funds and to healthcare companies in Africa, India, and South-East Asia.
Rehan is a graduate of the Advanced Management Program at Harvard Business School. He holds a Master of Science degree in Health Sciences from the Harvard-MIT Division of Health Sciences – a joint program between Harvard Medical School and MIT. The program included a 6-month rotation in Oncology at Massachusetts General Hospital. Rehan also has a Master of Business Administration degree from Drexel University and a Bachelor of Science degree from the University of Wisconsin.
For more than a century, MSD, a leading global biopharmaceutical company has been inventing for life, bringing forward medicines and vaccines for the world's most challenging diseases. MSD is a trading name of Merck & Co., Inc., with headquarters in Kenilworth, N.J., U.S.A.
Through its prescription medicines, vaccines, biologic therapies and animal health products, the company work with customers and operate in more than 140 countries to deliver innovative health solutions. It also demonstrates its commitment to increasing access to health care through far-reaching policies, programs and partnerships.
Today, MSD continues to be at the forefront of research to advance the prevention and treatment of diseases that threaten people and communities around the world - including cancer, cardiometabolic diseases, emerging animal diseases, Alzheimer's disease and infectious diseases including HIV and Ebola.
Since its existence in the India region, the company has moved quickly in laying the foundation for a business that is differentiated by its focus through launching innovative products relevant to India region.
Read also Fortis appoints Dr Farid Bin Mohamed Sani as additional director
Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers. Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd